The strong beat and raised guidance should drive positive momentum in the near term. Monitor upcoming quarters for continued operating leverage and progress toward profitability; the ATM program remains a potential dilution risk.
Price Chart
Executive Summary
Biodesix reported Q1 2026 revenue of $25.6M (+42% YoY) and EPS of -$0.49, beating consensus estimates of $23.2M and -$1.10 by 10% and 55% respectively. The company raised FY2026 revenue guidance to $108-114M (midpoint +25% YoY), and gross margin improved to 84% (82% ex-one-time items). Despite continued net losses, the strong beat and raised guidance signal accelerating growth and a clear path to profitability.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $25.6M (+42% YoY, beat $23.2M consensus)
- EPS -$0.49 vs consensus -$1.10 (55.3% beat)
- Diagnostic Testing revenue $22.3M (+37% YoY), volumes +29%
- Development Services revenue $3.3M (+99% YoY)
- Gross margin 84% (82% ex-one-time recovery of $0.4M)
- Net loss improved 30% to $7.8M; Adjusted EBITDA loss improved 35% to $4.1M
- Raised FY2026 revenue guidance to $108-114M (midpoint +25%)
- Cash and equivalents $25.6M, increased 35% QoQ partly from $16.8M ATM proceeds
Financial Impact
Revenue beat by $2.4M (10%) and EPS beat by $0.61 (55%); raised guidance midpoint by $2M
Risk Factors
- Still loss-making with net loss of $7.8M in Q1
- Cash burn and reliance on ATM program for funding (raised $16.8M in Q1)
- Dilution from potential further equity issuance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $23.87 | awaiting T+20 | — | $21.37 (−10.48%) |
Oct 19, 2026 8d ago | Press Release | $23.40 | awaiting T+20 | — | $21.37 (−8.68%) |
Aug 15, 2026 10w ago | Institutional Cluster | $23.25 $27.70 | ▲ +19.14% | ▲ +21.12% | $21.37 (−8.09%) |
Aug 13, 2026 10w ago | Insider Buy | $24.00 $27.40 | ▲ +14.17% | ▲ +16.16% | $21.37 (−10.96%) |
Aug 12, 2026 10w ago | Insider Buy | $23.79 $26.97 | ▲ +13.35% | ▲ +15.09% | $21.37 (−10.17%) |
Aug 5, 2026 11w ago | 8-K | $22.10 $26.48 | ▲ +19.80% | ▲ +19.20% | $21.37 (−3.30%) |
Jun 1, 2026 21w ago | EFFECT | $15.27 $22.55 | ▲ +47.68% | ▲ +48.97% | $21.37 (+39.94%) |
May 4, 2026 25w ago | Press Release | $14.94 $15.44 | ▲ +3.35% | ▼ −1.61% | $21.37 (+43.04%) |
Apr 20, 2026 27w ago | Press Release | $13.17 $14.25 | ▲ +8.20% | ▲ +4.00% | $21.37 (+62.26%) |
Mar 20, 2026 31w ago | Press Release | $14.88 $13.17 | ▼ −11.46% | ▼ −20.78% | $21.37 (+43.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers